Global Pegfilgrastim Biosimilar Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Pegfilgrastim Biosimilar Market Research Report 2024
Pegfilgrastim is developed by PEGylating the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, filgrastim. Pegfilgrastim was first launched by Amgen Inc. as Neulasta in 2002. Later, several biosimilars of pegfilgrastim were launched in the market. Pegfilgrastim is used as a supportive oncology drug to treat chemotherapy- and/or radiotherapy-induced neutropenia in cancer patients. With more than ten pegfilgrastim biosimilars available in the market and over 5 under development, the pegfilgrastim biosimilar size market is expected to witness an upswing in the future.
According to Mr Accuracy reports’s new survey, global Pegfilgrastim Biosimilar market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Pegfilgrastim Biosimilar market research.
Key manufacturers engaged in the Pegfilgrastim Biosimilar industry include Novartis, Mylan, Coherus BioSciences, Mundipharma International, Biocon, Intas Pharmaceuticals, Pfizer and Dr Reddy’s Laboratories, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Pegfilgrastim Biosimilar were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Pegfilgrastim Biosimilar market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Pegfilgrastim Biosimilar market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
![](http//localhost/mraccuracy/images/Market%20Recearch%20Graph.jpg)
Novartis
Mylan
Coherus BioSciences
Mundipharma International
Biocon
Intas Pharmaceuticals
Pfizer
Dr Reddy’s Laboratories
Segment by Type
Chemotherapy Treatment
Transplantation
Hospital Pharmacies
Mail-Order Pharmacies
Retail Pharmacies
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Pegfilgrastim Biosimilar report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source![](http://localhost/mraccuracy/images/About Report.webp)
According to Mr Accuracy reports’s new survey, global Pegfilgrastim Biosimilar market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Pegfilgrastim Biosimilar market research.
Key manufacturers engaged in the Pegfilgrastim Biosimilar industry include Novartis, Mylan, Coherus BioSciences, Mundipharma International, Biocon, Intas Pharmaceuticals, Pfizer and Dr Reddy’s Laboratories, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Pegfilgrastim Biosimilar were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Pegfilgrastim Biosimilar market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Pegfilgrastim Biosimilar market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
![](http//localhost/mraccuracy/images/Market%20Recearch%20Graph.jpg)
By Company
Novartis
Mylan
Coherus BioSciences
Mundipharma International
Biocon
Intas Pharmaceuticals
Pfizer
Dr Reddy’s Laboratories
Segment by Type
Chemotherapy Treatment
Transplantation
Segment by Application
Hospital Pharmacies
Mail-Order Pharmacies
Retail Pharmacies
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Pegfilgrastim Biosimilar report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
![](http://localhost/mraccuracy/images/About Report.webp)